Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU9800558Aexternal-prioritypatent/HUT77739A/en
Priority claimed from PCT/JP1995/000001external-prioritypatent/WO1996020706A1/en
Application filed by Torii Pharmaceutical Co LtdfiledCriticalTorii Pharmaceutical Co Ltd
Priority to NO973116ApriorityCriticalpatent/NO973116L/en
Publication of NO973116D0publicationCriticalpatent/NO973116D0/en
Publication of NO973116LpublicationCriticalpatent/NO973116L/en
239000003795chemical substances by applicationSubstances0.000abstract1
150000003839saltsChemical class0.000abstract1
Landscapes
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Det beskrives et trombolytisk middel som kan bli tilført oralt, der det nevnte middel omfatter 6-amidino-2-naftyl-4-[(4,5-dihydro-1 H-imidazol-2-yl)-amino]benzoat eller et farmasøytisk akseptabelt syreaddisjonssalt av dette.There is disclosed a thrombolytic agent which may be administered orally, said agent comprising 6-amidino-2-naphthyl-4 - [(4,5-dihydro-1H-imidazol-2-yl) amino] benzoate or a pharmaceutical acceptable acid addition salt thereof.
USE OF 5'-DEOXI-5'-METHYL-THIOADENOSINE, S-ADENOSYLMETIONINE AND ITS SALTS FOR THE PREPARATION OF REDUCING PHARMACEUTICAL COMPOSITIONS OF SEBORRHEA.
N-methyl-N - [(1S) -1-phenyl-2 - ((3S) -3-hydroxypyrrolidin-1-yl) -ethyl] -2,2-diphenylacetamide hydrochloride, drug containing the compound, use of the drug for the preparation of pharmaceutical preparations, pharmaceutical preparations containing l